Basal Cell Cancer (BCC) is the most common cancer in the world, affecting an estimated 2 million Americans annually. The Incidence of BCC is rising exponentially, with the percentage rise in incidence at 8% in 2006 going up every year. Historically, surgery and cautery were the only treatment options available. Contemporary treatments of straightforward BCC lesions still revolve around these two principles. However, they are more refined; incorporating histopathological analysis and modern surgical techniques allowing us to achieve better cosmetic and functional results. Recent developments in Genomics and the discovery in the role of the Sonic hedgehog (SHh) pathway in the pathomechanism of BCC, has allowed for the invention of Vismodogib; a first-in-class biological therapy inhibiting this pathway, allowing us to treat more complex BCC cases that were until recently dealt with palitively. The purpose of this work is to explain the treatment options available in the management of BCC and their context.